• Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 637.70 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.22
▼ -0.01 (-0.81%)

This chart shows the closing price for AVGR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avinger Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVGR

Analyst Price Target is $9.00
▲ +637.70% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Avinger in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 637.70% upside from the last price of $1.22.

This chart shows the closing price for AVGR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Avinger. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2022B. RileyLower Target$11.00 ➝ $9.00High
3/18/2022B. RileyLower TargetBuy$40.00 ➝ $11.00Medium
11/15/2021AegisLower TargetBuy$50.00 ➝ $40.00Low
9/1/2021B. RileyReiterated RatingBuy$50.00Medium
6/29/2021B. RileyInitiated CoverageBuy$50.00High
2/15/2021AegisReiterated RatingBuyHigh
1/19/2021AegisBoost TargetBuy$20.00 ➝ $50.00High
9/16/2020AegisLower TargetBuy$28.00 ➝ $20.00High
6/29/2020AegisReiterated RatingBuy$28.00Medium
6/2/2020AegisReiterated RatingBuyHigh
5/15/2020AegisLower TargetBuy$43.00 ➝ $28.00Medium
4/13/2020LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralMedium
3/9/2020AegisLower TargetBuy$60.00 ➝ $43.00High
9/12/2019AegisInitiated CoverageBuyHigh
3/9/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ BuyMedium
(Data available from 12/10/2017 forward)

News Sentiment Rating

-0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/11/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/11/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/10/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Avinger logo
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $1.22
Low: $1.20
High: $1.26

50 Day Range

MA: $1.14
Low: $0.96
High: $1.30

52 Week Range

Now: $1.22
Low: $0.94
High: $11.80

Volume

34,240 shs

Average Volume

105,966 shs

Market Capitalization

$9.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Avinger?

The following Wall Street research analysts have issued reports on Avinger in the last year: B. Riley, and StockNews.com.
View the latest analyst ratings for AVGR.

What is the current price target for Avinger?

1 Wall Street analysts have set twelve-month price targets for Avinger in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 637.7%. B. Riley has the highest price target set, predicting AVGR will reach $9.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $9.00 for Avinger in the next year.
View the latest price targets for AVGR.

What is the current consensus analyst rating for Avinger?

Avinger currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVGR will outperform the market and that investors should add to their positions of Avinger.
View the latest ratings for AVGR.

What other companies compete with Avinger?

How do I contact Avinger's investor relations team?

Avinger's physical mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The medical device company's listed phone number is (650) 241-7900 and its investor relations email address is [email protected] The official website for Avinger is www.avinger.com. Learn More about contacing Avinger investor relations.